Appendix 4E and Annual Report

Key points

• Revenues from ordinary activities up 43.9% to $1,684,978
• Loss from ordinary activities after tax down 28.1% to $(10,860,122)
• No dividends paid, recommended or declared
• Approval by Australia's TGA for pancreatic cancer treatment
• FDA HDE approval for distal cholangiocarcinoma treatment

Full summary

OncoSil Medical Ltd's financial year ended 30 June 2026 saw a 43.9% increase in revenues from ordinary activities to $1,684,978, and a 28.1% decrease in loss from ordinary activities after tax to $(10,860,122). The company did not pay, recommend, or declare any dividends. Significant regulatory milestones included approval by Australia's TGA for the treatment of unresectable locally advanced pancreatic cancer and FDA HDE approval for distal cholangiocarcinoma treatment. The company anticipates launching in Australia in the first half of 2027 and in the U.S. in the first half of 2027.